STATEMENT OF NEED
Type 2 diabetes is a complex disease that presents diverse challenges to those who provide diabetes care. The progressive loss of pancreatic islet-cell function and the accompanying chronic hyperglycemia, which are characteristic of type 2 diabetes, lead to the accumulation of microvascular and macrovascular tissue damage. There is growing evidence that treatment strategies that preserve islet-cell function can prevent or delay the development of type 2 diabetes. Evidence also indicates that tight control of hyperglycemia through individualized glucose-lowering therapies can greatly reduce microvascular damage, while maximal reduction of macrovascular risk is achieved through comprehensive treatment strategies that concurrently target hyperglycemia, hypertension, and dyslipidemia.

This webcast will inform participants of the most recent evidence concerning diabetes prevention, islet-cell preservation early in the course of type 2 diabetes, and strategies to achieve optimal reduction of microvascular and macrovascular risk in established patients, including the most recent update to the American Diabetes Association (ADA )/European Association for the Study of Diabetes (EASD) consensus algorithm.

TARGET AUDIENCE
This activity is designed for primary care physicians, endocrinologists, cardiologists, physician assistants, nurse practitioners, nurses, pharmacists, and certified diabetes educators. There is no fee to participate in this activity.

LEARNING OBJECTIVES
By the end of this activity, the participant should be better able to:

1. Implement glucose-lowering strategies that are appropriate for the individual needs and characteristics of each patient

2. Intensify glucose-lowering therapy whenever A1C is above 7.0% by utilizing the combinations of glucose-lowering agents that are most appropriate for individual patients

3. Screen and identify patients who would benefit most from implementing a treatment strategy to preserve pancreatic islet-cell function

4. Utilize the most up-to-date recommendations for treating hypertension and dyslipidemia concurrently with glycemic therapy in type 2 diabetes patients

ACCREDITATION AND DESIGNATION
Physicians:
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the cosponsorship of the Texas Academy of Family Physicians (TAFP) and TCL Institute, LLC. The TAFP is accredited by the ACCME to provide continuing medical education for physicians.

The TAFP designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in this activity.

This activity has been reviewed and is acceptable for up to 2.0 Prescribed credit(s) by the American Academy of Family Physicians (AAFP). Of these credits, 1.0 conform(s) to the AAFP criteria for evidence-based CME (EB CME) clinical content. CME credit has been increased to reflect 2 for 1 credit for only the EB CME portion. When reporting CME credit, AAFP members should report total Prescribed and Elective credit earned for this activity. It is not necessary for members to label credit as EB CME for reporting purposes. EB credit is available until September 1, 2010.

The EB CME credit awarded for this activity was based on practice recommendations that were the most current with the strongest level of evidence available at the time this activity was approved. Since clinical research is ongoing, the AAFP recommends that learners verify sources and review these and other recommendations prior to implementation into practice.

Physician Assistants:
Physician assistants can claim 1 AMA PRA Category 1 Credit(s)™.

Nurse Practitioners:
Nurse practitioners can claim 1 AMA PRA Category 1 Credit(s)™.

Nurses:
TCL Institute, LLC is a provider approved by the California Board of Registered Nursing, Provider Number 15225, for 1.2 contact hours.

RNs outside of California must verify with their licensing agency for approval of this course.

Certified Diabetes Educators:
The TAFP is accredited as a provider of continuing education by the ACCME . To satisfy the requirement for renewal of certification by continuing education for the National Certification Board for Diabetes Educators (NC BDE), continuing education activities must be diabetes related and approved by a provider on the NC BDE List of Recognized Providers. NC BDE (http://www.ncbde.org) does not approve continuing education. The TAFP is accredited as a provider of continuing education by the ACCME , which is on the NC BDE List of Recognized Providers.

FACULTY CHAIR
Patrick J. Boyle, MD
Professor of Medicine
University of New Mexico
Albuquerque, NM

DISCLOSURES
In accordance with the ACCME , the TAFP requires that any person who is in a position to control the content of a CME activity must disclose all relevant financial relationships they have with a commercial interest.

Accordingly:

Dr. Boyle reported that he is a speaker for Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; and Takeda Pharmaceuticals North America, Inc.

Mark Richardson, PhD, medical writer for TCL Institute, LLC, has nothing to disclose.

The TAFP and TCL Institute staff that were involved in the development of this activity have no financial relationships with any commercial interest that are relevant to this activity.

To resolve identified conflicts of interest, the educational content was fully peer-reviewed by a physician member of the TAFP Clinical Content Review Committee who has nothing to disclose. The resulting certified activity was found to provide educational content that is current, evidence-based, and commercially balanced.

DISCLOSURE OF UNLABELED OR INVESTIGATIONAL DRUGS
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

DISCLAIMER
The material presented in all activities is offered solely for educational purposes. TAFP, Takeda Pharmaceuticals North America, Inc., and TCL Institute, LLC disclaim any and all claims that may result from use of information presented in this activity. Material contained herein may be graphic, but is intended for clinical use. It is the policy of TAFP that all CME planning committee members and TAFP and TCL Institute staff disclose relationships with commercial entities. Disclosure documents are reviewed for potential conflict of interests and if a conflict is identified it is resolved prior to confirmation of participation. Only those participants who have no conflict of interest or who agree to an identified resolution process prior to their participation were involved in this CME activity.

Please Click Here to Begin the Activity